A new innovative medical stock is starting to gain investor and consumer interest in the United States in 2016. But before you get into this micro cap opportunity, watch this video till the end to find out how this tiny company could become the next big thing in no time.
According to the National Sleep Foundation, only 56% of Americans say they get a good night’s sleep on a typical work or school night – that means almost half the country is restless, uncomfortable and looking for a solution.
The number one complaint of people making use of sleeping pills is the daytime sedation they experience after the fact – feeling drowsy in the morning and throughout the day. Secondarily, most pills do little to address the stress instead “forcing” their bodies to sleep by depressing the central nervous systems.
Many branded sleeping pills currently on the market come with serious side effects too – ranging from dizziness and nausea to sleepwalking and loss of short term memory – something that has people uncomfortable, but there’s little choice in the current market.
It’s estimated that in 2011 alone, 40 million prescriptions for sleeping aids were dispensed – sales of generic Ambien (zolpidem tartrate) came to $2.8 billion dollars while Lunesta amounted in another $912 million.
Current issues aside, prescription sleep aids are some of the most heavily marketed drugs and while the need for them is only increasing, not a lot of alternatives have been offered – alternatives that would put the minds of consumers at ease and change the market as we know it.
Could This New Sleep Aid Change the Industry as We Know it?
That’s where Zleepax from Blake Insomnia Therapeutics Inc. ( Stock Symbol: BKIT – website) comes in. Zleepax is a patent-pending innovative sleeping pill with beta blockers as the major active ingredient which addresses stress related insomnia as one of the first sleeping pills ever to focus on this specific cause of sleep disorders. Unlike a lot of other medications with severe side effects, Zleepax (Stock Symbol: BKIT) uses third generation beta blockers, which have been shown to have milder side effects and work excellently as a sleep enhancer. Their special patent applications (using beta blockers like Nebivolol) have been shown to specifically target the most common form of sleep disorder, i.e. focusing on stress-related insomnia instead of merely ignoring the source and treating the symptoms. While other medications can be dangerously addictive, have tolerance build-up and create residual daytime sedation, Zleepax (Stock Symbol: BKIT) has been able to formulate a solution that dramatically reduces those concerns, with minimal side effects to boot. Zleepax touts a number of competitive advantages:
- No cognitive impairment
- No respiratory depression
- No tolerance build-up
- No physical dependence or abuse
- No reaction with alcohol or prescription medication
- No rebound insomnia withdrawal
The company behind Zleepax – Blake Insomnia Therapeutics Inc. (Stock Symbol: BKIT) is not just another start-up with a revolutionary idea.
The initial work on Zleepax started in 2007 by CEO and industry innovator Birger Jan Olsen and through years of research they ended up filing patent applications PCT/DK2008/000249 and EP20080758258, covering the use of specific beta blockers (alone or in combination with other anti-insomnia drugs) for the treatment of stress-related insomnia. BKIT‘s business model is not to compete with the big pharmaceutical companies – in fact, the model is simple. They will finalize the product development, team up with a major pharmaceutical company (like GSK, Merck etc.) and enter into a license agreement, thereby taking advantage of the big players access to distribution and marketing. This route leaves BKIT as the patent holder with recurrent income streams for years and years to come.
The Market is Waking Up – Is it the right time for Zleepax and BKIT?
The medical industry is booming and most seasoned investors keep that in mind when building their stock portfolios.
Can you imagine yourself being given the opportunity to invest in GSK, Merck and Lundbeck when they were just coming out onto the market and shares were going for just a fraction of what they are today?
CNN Money reported that 4 out of 5 of the Best Performing IPOs in 2015 have been pharmaceutical companies including companies such as Spark Therapeutics Inc (ONCE) and Aduro BioTech Inc,( ADRO).
Did you miss out? If so, BKIT might just be your chance to not miss out again.
Here’s another success story – in 2005, Sunovion Pharmaceuticals Inc launched Lunesta (one of the most commonly prescribed sleep medications) and it generated $329 million in sales in it’s first nine months alone, an unprecedented amount for a new drug on the market and their success has only continued.
Between the increasing need for sleep aids, and the demand that side effects be lessened, Blake Insomnia Therapeutics, Inc. (BKIT) and its’ breakthrough sleeping pill Zleepax is perfectly poised to become a strong market player in this vastly growing industry. Some of the giants (GSK, Merck and Lundbeck) have all been forced to abandon planned follow-ups to their current sleep medications, which means there is a massive gap in the current industry, even as demand for sleep medication increases. Zleepax is already in clinical testing and dedicated to total compliance.
How To Get Started:
1. Watch the video in the begining of this article, check company’s website and stock quote. It will give you complete understanding about biotech market and investment trends.
2. Make sure you have a stock broker. If you don’t already have one, you can look at these 3 below. :
Disclaimer: This release/advertorial is a commercial advertisement and is for general information purposes only. This is a Native Advertisement, meaning it is an informational paid marketing piece. Finance-monthly.com makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Please review all investment decisions with a licensed investment advisor.
This Advertorial contains forward-looking statements that involve risks and uncertainties. This Advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured Company. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s)” “anticipate(s)”, “plan(s)” “expect(s)” “project(s)” “will” “make” “told” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cau se actual events or actual results of the Company to differ materially from these indicated by such forward-looking statements. Certain statements contained herein constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business, financing, business trends, future operating revenues and expenses. There can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the Company, or contained in this advertorial are not guarantees of future performance, and that the Issuer’s actual results may differ materially from those set forth in the forward-looking statements. Difference in results can be caused by various factors including, but not limited to, the Company’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this advertorial contains “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this advertorial may be identified through the use of words such as “expects,” “will,” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating certain actions “may,” “could,” or “might” occur. More information on the Company may be found at http://www.sec.gov; readers can review all public filings by the Company at the SEC’s EDGAR page. Finance-monthly.com is not certified financial analysts or licensed in the securities industry in any manner. The information in this Advertorial is subjective opinion and may not be complete, accurate or current and was paid for, so this could create a conflict of interest.